Thomas Prebet, MD, PhD
Associate Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
About
Titles
Associate Professor Adjunct
Biography
After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and translational works for advanced phase acute myeloid leukemia and myelodysplastics syndromes. The current works gave the basis for defining demethylating agent failure outcome (Prebet JCO 2011, Hematologica 2012, British Journal of Hematology 2012, Blood Advance 2018), contributed to his knowledge of combinations therapies based on HDAC inhibitors (Prebet JCO 2014, Prebet Leuk Res 2014) and gave the first insights on the implication of Wnt non canonical pathway in acute myeloid leukemia (Prebet Blood 2011). Dr Prebet is the coordinating investigator of several clinical trials for myelodysplastic syndromes and acute leukemia patients and contributed to 110 peer reviewed manuscript.
Appointments
Hematology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Hematology
- Internal Medicine
- Yale Medicine
Education & Training
- Post-Doctoral Fellow
- Johns Hopkins University (2010)
- PhD
- Centre de Recherche en Cancerologie (2009)
- MS
- Claude Bernard University (2005)
- Resident
- University Hospitals of Lyon (2004)
- MD
- Montpellier University (2000)
Research
Overview
Medical Research Interests
Hematology; Leukemia; Myelodysplastic Syndromes
ORCID
0000-0002-6872-625X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Thomas Prebet's published research.
Publications Timeline
A big-picture view of Thomas Prebet's research output by year.
Research Interests
Research topics Thomas Prebet is interested in exploring.
Amer Zeidan, MBBS
Jan Philipp Bewersdorf, MD
16Publications
706Citations
Myelodysplastic Syndromes
Publications
2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.Peer-Reviewed Original ResearchConceptsRelapse-free survivalNewly diagnosed acute myeloid leukemiaOral-AZAIntensive chemotherapyAcute myeloid leukemiaOverall survivalMyeloid leukemiaMedian relapse-free survivalFlatiron Health databasePropensity score matched cohortCompare treatment patternsScore-matched cohortAzacitidine maintenanceND-AMLOral azacitidineMedian OSRetrospective studyClinical outcomesTreatment patternsAzacitidineTransplant candidatesPatientsReal-world outcomesRemissionChemotherapyLenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Post-Authorization Safety Surveillance Study
Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Post-Authorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.Peer-Reviewed Original ResearchConceptsInternational Prognostic Scoring SystemDose of lenalidomideMyelodysplastic syndromeIsolated del(5qAcute myeloid leukemiaBenefit-risk profileSafety populationTransfusion-dependentOverall survivalCumulative incidenceCumulative incidence of acute myeloid leukemiaGrade 3/4 treatment-emergent adverse eventsNon-interventional post-authorization safety studyInternational Prognostic Scoring System low-Intermediate-1-risk myelodysplastic syndromeIncidence of acute myeloid leukemiaLower-risk myelodysplastic syndromesTreatment-emergent adverse eventsEffects of lenalidomidePrognostic Scoring SystemKaplan-Meier analysisPost-authorization safety studyRoutine careClinical trial dataSafety surveillance studyHealthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study
Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study. Advances In Therapy 2024, 41: 4049-4064. PMID: 39240504, PMCID: PMC11480148, DOI: 10.1007/s12325-024-02947-1.Peer-Reviewed Original ResearchAltmetricConceptsAcute myeloid leukemiaHealthcare resource utilizationOral-AZAPropensity score matchingMyeloid leukemiaReal-world healthcare resource utilizationClinical practiceHematopoietic stem cell transplantationLower healthcare resource utilizationResultsAfter propensity score matchingStem cell transplantationContinuous insurance enrollmentClaims database studyOutpatient visitsOral azacitidinePost-remissionMaintenance therapyProlonged remissionCell transplantationDisease remissionDelayed relapseBaseline characteristicsTreatment patternsPatientsDatabase studyLuspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Della Porta M, Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. The Lancet Haematology 2024, 11: e646-e658. PMID: 39038479, DOI: 10.1016/s2352-3026(24)00203-5.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLower-risk myelodysplastic syndromesRed blood cell transfusion independenceTreatment-emergent adverse eventsMedian follow-upEpoetin alfa groupMyelodysplastic syndromeLuspatercept groupTransfusion-dependentSerum erythropoietin concentrationPrimary endpointEpoetin alfaTransfusion independenceOpen-labelAlfa groupAdverse eventsFollow-upRed blood cell transfusion burdenErythropoietin concentrationIntention-to-treat populationControlled trialsCommon grade 3Epoetin alfa recipientsMean haemoglobin increasePrimary analysisProportion of patientsA post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.
Voso M, De Botton S, Pfeilstöcker M, Figuera Alvarez A, Wang K, L. See W, Ugidos Guerrero M, Lopes de Menezes D, Petrlik E, Prebet T, Roboz G. A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study. Journal Of Clinical Oncology 2024, 42: 6522-6522. DOI: 10.1200/jco.2024.42.16_suppl.6522.Peer-Reviewed Original ResearchConceptsRelapse-free survivalHematopoietic stem cell transplantationOral-AZAPoor-risk cytogeneticsAML-MRCOutcomes of patientsMedian OSOverall survivalTreatment armsMedian relapse-free survivalAnalysis of outcomes of patientsProlonged median OSMyelodysplasia-related changesStem cell transplantationPhase 3 studyKaplan-Meier methodAcute myeloid leukemiaEffective treatment optionYears of agePost hoc analysisOral azacitidinePlacebo QDImproved OSMRD negativitySecondary AMLPreliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.
Garcia-Manero G, Yee K, Hernandez F, Della Porta M, Paolini S, Ahn S, Santini V, Fenaux P, Suzuki T, Sekeres M, He J, Li J, Barkalifa R, Vigil C, Prebet T, Lopes de Menezes D, Burnett J, Komrokji R, Giagounidis A. Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial. Journal Of Clinical Oncology 2024, 42: 6509-6509. DOI: 10.1200/jco.2024.42.16_suppl.6509.Peer-Reviewed Original ResearchConceptsLower-risk MDSOral-AZAMyelodysplastic syndromeAdverse eventsPreliminary efficacy dataComplete remissionEfficacy dataOverall responseLower-risk myelodysplastic syndromesHigher-risk myelodysplastic syndromesIPSS-R scoreRBC transfusion burdenRate of adverse eventsDose-optimization studyErythropoiesis-stimulating agentsSerious adverse eventsAcute myeloid leukemiaMITT populationOral azacitidineTransfusion burdenIPSS-ROpen-labelEligible ptsPhase 2/3Primary endpointDifferentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials
Montesinos P, Fathi A, de Botton S, Stein E, Zeidan A, Zhu Y, Prebet T, Vigil C, Bluemmert I, Yu X, DiNardo C. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Advances 2024, 8: 2509-2519. PMID: 38507688, PMCID: PMC11131052, DOI: 10.1182/bloodadvances.2023011914.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAcute myeloid leukemiaDevelopment of differentiation syndromeRisk factorsPooled analysisIDH2-mutant acute myeloid leukemiaClinical trialsAcute myeloid leukemia populationMedian time to onsetClinical features of DSBone marrow blastsNon-specific symptomsTime to onsetBaseline risk factorsTreatment of DSSymptoms of DSIdentified risk factorsFeatures of DSMarrow blastsSystemic steroidsPulmonary infiltratesClinical responseMutant IDH2 inhibitorMyeloid leukemiaClinical featuresGrade 3Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Risueño A, See W, Bluemmert I, de Botton S, DiNardo C, Fathi A, Schuh A, Montesinos P, Vyas P, Prebet T, Gandhi A, Hasan M. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leukemia Research 2024, 140: 107497. PMID: 38564986, DOI: 10.1016/j.leukres.2024.107497.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsConventional care regimensMutational burdenR/R AMLCo-mutationsIDH2-R172Co-mutation patternsAssociated with decreased overall survivalRelapsed/refractory acute myeloid leukemiaTargeted next-generation sequencingAML patient cohortNewly diagnosed AMLLow mutational burdenEvent-free survivalLimited treatment optionsAcute myeloid leukemiaGene mutation patternsIDH2 variantsIDH2 R140Prognostic impactOverall survivalPrognostic relevanceSurvival benefitMyeloid leukemiaIDH2 mutationsPatient cohortCorrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]
Mims A, Xie Z, Vasconcelos A, Strocchia M, Heydendael W, Chevli M, Rotter D, Potluri R, Prebet T, Sieluk J. Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 203-204. DOI: 10.1016/j.clml.2023.11.010.Peer-Reviewed Original ResearchEFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
Garcia-Manero G, Platzbecker U, Santini V, Zeidan A, Fenaux P, Komrokji R, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Degulys A, Paolini S, Cluzeau T, Della Porta M. EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL. Leukemia Research Reports 2024, 21: 100447. DOI: 10.1016/j.lrr.2024.100447.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesTreatment-emergent adverse eventsEA-treated patientsRBC-TIPrimary endpointHI-ERed blood cell transfusion independenceHematological improvement-erythroidTransfusion independenceErythroid responseMyelodysplastic syndromeSecondary endpointsAdverse eventsFull analysisLuspaterceptAssessed efficacySafety resultsEpoetin alfaTreatment durationPatientsEndpointEfficacyDurationPost-treatmentAML
Clinical Trials
Current Trials
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
HIC ID2000025634RoleSub InvestigatorPrimary Completion Date07/06/2023Recruiting Participants
Academic Achievements & Community Involvement
activity National Cancer Center Network
CommitteesCommittee MemberDetailsAML committee10/01/2017 - Presentactivity Yale Human Research Protection Program
CommitteesCommittee MemberDetailsHuman Investigation Committee12/31/2016 - Presentactivity Via Pathway Oncology
Peer Review Groups and Grant Study SectionsCo-ChairDetails2018 - Presentactivity National Comprehensive Cancer Network
Peer Review Groups and Grant Study SectionsCommittee MemberDetails2018 - Presentactivity Onco Hematology for Fullbright commission (French American scholar exchange commission)
Peer Review Groups and Grant Study SectionsMemberDetails2011 - Present
News
News
- June 16, 2021
Discoveries & Impact (June 2021)
- March 10, 2021
Discoveries & Impact (March 2021)
- January 31, 2021
Winners Announced for Annual Yale Cancer Center Conclave Awards
- May 25, 2020Source: The ASCO Post
Yale Cancer Center Announces Hematology Leadership Appointments
Get In Touch
Contacts
Appointment Number
Clinic Fax Number